Market Size of Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 203.89 Million |
| Market Size (2029) | USD 266.48 Million |
| CAGR (2024 - 2029) | 5.50 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Latin America Glucagon-like Peptide-1 Agonists Market Analysis
The Latin America Glucagon-like Peptide-1 Agonists Market size is estimated at USD 203.89 million in 2024, and is expected to reach USD 266.48 million by 2029, growing at a CAGR of 5.5% during the forecast period (2024-2029).
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used for the treatment of type 2 diabetes and some drugs are also approved for obesity. One of the benefits of this class of drugs over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia.
Besides being important glucose-lowering agents, GLP-1RAs have significant anti-inflammatory and pulmonary protective effects and an advantageous impact on gut microbes' composition. Therefore, GLP-1RAs have been potential candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.
The diabetic prevalence is high in countries in the Latin American region, and Mexico is known to have a high number of diabetic patients due to the growing prevalence of Type-2 diabetes in the country. The gradually growing obesity rate, combined with the genetic predisposition for Type-2 diabetes, acted as a prominent driver for the increase in the Type-2 diabetic population over the last 40 years. Currently, nearly 10% of the population is living with diabetes. Diabetic patients in the Latin American region mainly suffer from Type-2 diabetes, accounting for nearly 90% of the total diabetic population.
According to the IDF Diabetes Atlas, the prevalence of diabetes in Mexico reached 16.9%, or one in six adults. Additionally, 11 million adults in the country have impaired glucose tolerance, which places them at high risk of developing type-2 diabetes. Diabetes-related health expenditure in Mexico has put it in the top ten countries or territories with the highest total health expenditure. Under half of the people living with diabetes in the country are undiagnosed.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Latin America Glucagon-like Peptide-1 Agonists Industry Segmentation
GLP-1 receptor agonists are a type of non-insulin medication that is used in combination with diet and exercise to help treat type-2 diabetes. The Latin America glucagon-like peptide-1 (GLP-1) agonists market is segmented by drugs, brands, and geography . The report offers the value (in USD) and volume (in units) for the above segments.
| Drugs | ||||
| ||||
| ||||
| ||||
| ||||
|
| Geography | |
| Brazil | |
| Mexico | |
| Rest of Latin America |
Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market Size Summary
The Latin America glucagon-like peptide-1 (GLP-1) agonists market is poised for significant growth, driven by the increasing prevalence of type 2 diabetes and obesity in the region. GLP-1 receptor agonists are gaining traction due to their dual benefits of managing blood glucose levels and offering cardiovascular protection, making them a preferred choice over traditional insulin secretagogues. The market is characterized by the dominance of key players such as Eli Lilly, AstraZeneca, and Novo Nordisk, who are actively expanding their presence in major Latin American countries. The introduction of new therapies and the approval of drugs like Zepbound for weight management are expected to further stimulate market expansion.
Mexico and Brazil are at the forefront of this market growth, with Mexico anticipated to register the highest compound annual growth rate. The high diabetic prevalence, particularly in Mexico, coupled with government initiatives like community-based health insurance, is expected to enhance access to GLP-1 therapies. These medications are not only effective in controlling diabetes but also play a crucial role in reducing the risk of diabetes-related complications, thereby improving the quality of life for patients. The market's growth is supported by ongoing clinical trials and the development of new drug combinations, which promise to enhance the efficacy and safety of diabetes management in the region.
Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.3 Market Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. Market Segmentation
-
2.1 Drugs
-
2.1.1 Exenatide
-
2.1.1.1 Byetta
-
2.1.1.2 Bydureon
-
-
2.1.2 Liraglutide
-
2.1.2.1 Victoza
-
-
2.1.3 Lixisenatide
-
2.1.3.1 Lyxumia
-
-
2.1.4 Dulaglutide
-
2.1.4.1 Trulicity
-
-
2.1.5 Semaglutide
-
2.1.5.1 Ozempic
-
-
-
2.2 Geography
-
2.2.1 Brazil
-
2.2.2 Mexico
-
2.2.3 Rest of Latin America
-
-
Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market Size FAQs
How big is the Latin America Glucagon-like Peptide-1 Agonists Market?
The Latin America Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 203.89 million in 2024 and grow at a CAGR of 5.5% to reach USD 266.48 million by 2029.
What is the current Latin America Glucagon-like Peptide-1 Agonists Market size?
In 2024, the Latin America Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 203.89 million.
